REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 28, 2015

Primary Completion Date

September 19, 2021

Study Completion Date

September 19, 2021

Conditions
Ovarian Carcinoma
Interventions
DRUG

Tamoxifen

Tamoxifen: 40 mg/day

DRUG

Regorafenib

Stivarga; 120mg/day

Trial Locations (21)

13009

Institut Paoli Calmettes, Marseille

22190

Centre CARIO - HPCA, Plérin

24004

Clinique Francheville, Périgueux

25030

Hôpital Jean Minjoz, Besançon

33076

Institut Bergonié, Bordeaux

37044

Centre Hospitalier Universitaire Bretonneau, Tours

40024

Hôpital de Mont-de-Marsan, Mont-de-Marsan

44202

Centre Catherine de Sienne, Nantes

44805

ICO Centre René Gauducheau, Saint-Herblain

45067

Centre Hospitalier Régional d'Orléans, Orléans

49300

Centre Hospitalier de Cholet, Cholet

51056

Institut Jean Godinot, Reims

54100

ORACLE - Centre d'Oncologie de Gentilly, Nancy

59020

Centre Oscar Lambret, Lille

63000

Centre Jean Perrin, Clermont-Ferrand

69373

Centre Léon Bérard, Lyon

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

74374

Centre Hospitalier Annecy Genevois, Pringy

75014

Institut Mutualiste Montsouris, Paris

87042

Centre Hospitalier Universitaire Dupuytren, Limoges

06250

Centre Azuréen de Cancérologie, Mougins

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

ARCAGY/ GINECO GROUP

OTHER